The role of HBIG in real life for patients undergoing liver transplantation due to HDV‐related cirrhosis

Author:

Rodríguez‐Tajes Sergio12ORCID,García‐Eliz María23,Marcos Arantxa Caballero4,Campos‐Varela Isabel5ORCID,Ros Alba Cachero6,Loinaz Carmelo7,Gómez Bravo Miguel Á.8,Rodríguez‐Perálvarez Manuel29,Fabrega Emilio10,González Diéguez María L.11,Vinaixa Carmen23ORCID,Pascasio José M.28,Vázquez Inmaculada Fernández7,Baliellas Carme6,Castells Lluis25,Salcedo Magdalena4,Prieto Martín23,Crespo Gonzalo12ORCID,Lens Sabela12ORCID,Forns Xavier12ORCID

Affiliation:

1. Liver Unit, Hospital Clínic University of Barcelona, IDIBAPS Barcelona Spain

2. Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas ISCIII Madrid Spain

3. Liver Unit Hospital Universitario y Politécnico de La Fe Valencia Spain

4. Liver Transplant Unit Gregorio Marañón Hospital Madrid Spain

5. Liver Unit Vall d'Hebron University Hospital Barcelona Spain

6. Liver Unit Bellvitge University Hospital L'Hospitalet de Llobregat Spain

7. Liver Transplant Unit University Hospital 12 de Octubre Madrid Spain

8. Liver Unit Virgen del Rocio Hospital Sevilla Spain

9. Liver Transplant Unit Hospital Universitario Reina Sofia Córdoba Spain

10. Liver Unit Marqués de Valdecilla University Hospital Santander Spain

11. Liver Unit Hospital Universitario Central de Asturias Oviedo Spain

Abstract

AbstractRecommended post‐liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti‐hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real‐life clinical practice and its impact on HBV/HDV recurrence in 174 HDV‐related LT patients from 10 Spanish liver transplant centres (1988–2018). Median post‐LT follow‐up was 7.8 (2.3–15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post‐LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7–52) months. Post‐LT HBsAg+ was detected in 16 (9%) patients and HBV‐DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV‐LT is feasible, especially if high‐barrier NAs are used.

Funder

Asociación Española para el Estudio del Hígado

Generalitat de Catalunya

Instituto de Salud Carlos III

Societat Catalana de Digestologia

Publisher

Wiley

Subject

Hepatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3